ScoreWhy is Theravance Biopharma, Inc. ?
1
With a growth in Net Sales of 83.75%, the company declared Very Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 245.01 MM
- ROCE(HY) Highest at 6.23%
- RAW MATERIAL COST(Y) Fallen by -6.56% (YoY)
2
With ROE of -32.43%, it has a risky valuation with a 3.39 Price to Book Value
- Over the past year, while the stock has generated a return of 100.00%, its profits have fallen by -23.4%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 100.00% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Theravance Biopharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Theravance Biopharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Theravance Biopharma, Inc.
90.04%
2.44
48.30%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.11%
EBIT Growth (5y)
13.27%
EBIT to Interest (avg)
-10.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
0.27
Tax Ratio
20.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.39
EV to EBIT
-9.87
EV to EBITDA
-11.24
EV to Capital Employed
6.16
EV to Sales
7.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-62.37%
ROE (Latest)
-32.43%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend38What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 245.01 MM
ROCE(HY)
Highest at 6.23%
RAW MATERIAL COST(Y)
Fallen by -6.56% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -130.02 %
DEBTORS TURNOVER RATIO(HY)
Highest at 4.26 times
NET SALES(Q)
Highest at USD 26.2 MM
OPERATING PROFIT(Q)
Highest at USD -1.38 MM
OPERATING PROFIT MARGIN(Q)
Highest at -5.25 %
PRE-TAX PROFIT(Q)
Highest at USD 73.21 MM
NET PROFIT(Q)
Highest at USD 54.84 MM
EPS(Q)
Highest at USD 1.08
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Theravance Biopharma, Inc.
Pre-Tax Profit
At USD 73.21 MM has Grown at 696.63%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 54.84 MM has Grown at 503.85%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 245.01 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 26.2 MM has Grown at 83.75%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
Highest at USD 26.2 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -1.38 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -5.25 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 73.21 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 54.84 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.08
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -130.02 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 4.26 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.56% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
